Tag Archives: PCI

Light-based enhancement of vaccination in humans

  Motivation Vaccines should activate all branches of immunity, including T cells and antibody responses, for generating a strong immune response. For therapeutic cancer vaccines, it is especially important to induce strong cytotoxic T-cell responses, since cytotoxic T-cells are the most potent immune cells for killing cancer cells. While cytotoxic T-cells can often be induced  with viral vector and nucleic acid-based vaccines, peptide-based vaccines often induce only weak cytotoxic T-cell responses . When peptide antigens are taken up into antigen presenting cells, they are generally Continue reading →Customer case PCI Biotech is a biopharmaceutical company located in Norway. They are developing a novel light-based technology called photochemical internalization (PCI) that has potential to enhance delivery and efficacy of many types of therapies, including certain chemotherapies, peptide vaccines, and nucleic acid therapies. It can also decrease side effects due to improved spatiotemporal control of the treatment. The technology is currently in a pivotal clinical study for the treatment of inoperable bile duct cancer where PCI with gemcitabine is combined with standard gemcitabine/cisplatin chemotherapy. Continue reading →